Recombinant Mouse Psychosine receptor (Gpr65)

What is GPR65 and what are its primary functions in physiological systems?

GPR65 (also known as T-cell death-associated gene 8 or TDAG8) is a proton-sensing G-protein-coupled receptor (PS-GPCR) that plays significant roles in inflammatory and immune processes. It functions as a pH sensor, becoming activated in acidic environments typical of inflammatory sites. When activated, GPR65 triggers multiple downstream signaling cascades that mediate inflammatory responses, including cytokine production and cellular activation .

In physiological systems, GPR65 has been implicated in:

• Mediating inflammatory joint pain through cell-cell interactions

• Coordinating immune cell function in acidic microenvironments

• Sensitizing sensory neurons in inflammatory conditions

• Possibly regulating T-cell apoptosis (hence its alternative name TDAG8)

Recent research has demonstrated that GPR65 on fibroblast-like synoviocytes (FLS) contributes to inflammatory joint pain by secreting proinflammatory mediators that sensitize sensory neurons and recruit additional immune cells .

How does psychosine interact with GPR65, and what are the alternative ligands for this receptor?

Known activators of GPR65 include:

• Protons (H+) - The primary physiological activator, functioning optimally at pH 6.0-6.5

• Psychosine - A glycosphingolipid that accumulates in Krabbe disease

• BTB09089 (BTB) - A synthetic agonist with high selectivity for GPR65

Notably, while protons and BTB both induce robust cAMP accumulation, calcium mobilization, ERK1/2 phosphorylation, and β-arrestin recruitment, psychosine shows a different signaling profile. For instance, psychosine fails to coordinate β-arrestin recruitment to GPR65 while still triggering receptor internalization, suggesting ligand-specific activation mechanisms .

What experimental methods are used to express and purify recombinant mouse GPR65?

Expression and purification of recombinant mouse GPR65 typically employs mammalian expression systems due to the complex post-translational modifications required for proper GPCR folding and function. The methodology involves:

• Vector Construction:

  • Cloning full-length mouse GPR65 cDNA into a mammalian expression vector

  • Including appropriate tags (such as V5 or polyhistidine) for detection and purification

• Cell Line Selection and Transfection:

  • Chinese Hamster Ovary (CHO) cells are commonly used for GPCR expression

  • Stable transfection followed by selection of high-expressing clones

• Expression Optimization:

  • Culturing in chemically defined medium in suspension

  • Fed-batch production with additional feeds and glucose over 10-14 days

• Purification Strategy:

  • Harvesting and filtering cell culture fluid

  • Two-step chromatographic purification using ion exchange (e.g., Capto Q) followed by hydrophobic interaction chromatography (e.g., Butyl Sepharose)

  • pH adjustment and sterile filtration

  • Concentration using centrifugal spin concentrators

This approach mirrors successful strategies used for other membrane proteins, including recombinant acid ceramidase production in CHO cells as described in the literature .

How can researchers effectively distinguish between GPR65-specific signaling and responses mediated by other proton-sensing receptors?

Differentiating GPR65-specific signaling from other proton-sensing receptors requires a multi-faceted approach that leverages selective tools and genetic models:

• Use of Selective Agonists:

  • BTB09089 (BTB) has been validated as a selective GPR65 agonist that recapitulates many proton-induced signaling events without activating other proton-sensing receptors

  • BTB shows activation only in cells expressing mGPR65 and not in control cells (mGPR65-CHO vs. CHO: P-adj < 0.0001)

• CRISPR/Cas9 Knockout Validation:

  • Generate GPR65 knockout cell lines to confirm specificity

  • Compare responses between wild-type, knockout, and rescued (re-expressing GPR65) cell lines

• Signaling Fingerprint Analysis:

  • Monitor multiple downstream pathways simultaneously (cAMP, Ca2+, ERK1/2, β-arrestin recruitment)

  • The specific pattern of activation across pathways can distinguish GPR65 from other proton sensors

  • For example, assess ERK1/2 phosphorylation in both parental and GPR65-expressing cells (pH 6: Flp-IN, 1.11 ± 0.15%, mGPR65-CHO, 39.51 ± 2.16%, t = −17.756, df = 2.018, P = 0.003)

• BRET-Based Interaction Assays:

  • Implement Bioluminescence Resonance Energy Transfer (BRET) assays to directly measure:

    • β-arrestin recruitment (using GPR65-RLuc8 and β-arrestin-YFP constructs)

    • Receptor internalization (using GPR65-RLuc8 and membrane-targeted RIT-Venus)

This comprehensive approach allows researchers to confidently attribute observed responses to GPR65 rather than other proton-sensing mechanisms.

What are the optimal experimental conditions for analyzing GPR65-mediated signaling in primary cell cultures?

Establishing optimal conditions for GPR65 signaling analysis in primary cells requires careful consideration of multiple parameters:

• pH Control and Buffering Systems:

  • Maintain precise pH control (typically pH 6.0-6.5 for proton activation)

  • Use Good's buffers (MES, PIPES) for stable pH maintenance

  • Include proper controls at physiological pH (7.2-7.4)

• Primary Cell Isolation and Culture:

  • For fibroblast-like synoviocytes (FLS): enzymatic digestion of synovial tissue with collagenase, followed by adherence selection

  • For sensory neurons: dissociation of dorsal root ganglia with specific growth factor supplementation

  • Maintain cells in serum-free conditions during experiments to avoid confounding factors

• Signaling Readout Selection:

  • cAMP accumulation: use ELISA or HTRF-based detection after phosphodiesterase inhibition

  • Ca2+ mobilization: employ ratiometric imaging with Fura-2 or fluorescent plate readers with Fluo-4

  • ERK1/2 phosphorylation: western blotting or in-cell western techniques

  • Cytokine secretion: multiplex assays to capture the full profile of released mediators

• Temporal Considerations:

  • Perform time-course experiments (5-60 minutes) to capture both early and late signaling events

  • For long-term outcomes, monitor cells for 24-72 hours under controlled conditions

• Pharmacological Tools:

  • Use BTB09089 at 1-10 μM as a selective GPR65 agonist

  • Include appropriate vehicle controls

  • Consider antagonist studies with emerging GPR65 inhibitors to confirm receptor specificity

These conditions allow for robust and reproducible analysis of GPR65 signaling in physiologically relevant primary cell systems.

How can recombinant GPR65 be functionally validated to ensure proper folding and signaling capacity?

Functional validation of recombinant GPR65 requires a systematic approach to confirm proper protein folding, membrane localization, and signaling competence:

• Conformational Analysis:

  • Circular dichroism spectroscopy to assess secondary structure

  • Limited proteolysis to evaluate the accessibility of protease sites

  • Thermal stability assays to determine protein stability

• Membrane Localization Assessment:

  • Confocal microscopy with fluorescently tagged GPR65

  • Surface biotinylation followed by western blotting

  • BRET assays using RIT-Venus as a plasma membrane marker

• Ligand Binding Assays:

  • Radioligand binding assays (if available)

  • Fluorescent ligand binding with FRET-based detection

  • Surface plasmon resonance for direct binding kinetics

• Signaling Competence Validation:

  • cAMP accumulation assays in response to protons, BTB09089, and psychosine

  • Dose-response curves across multiple signaling pathways

• Functional Reconstitution:

  • Expression in GPR65-null cells to rescue phenotypes

  • Comparison with native receptor responses in appropriate cell types

Through this comprehensive validation approach, researchers can ensure that recombinant GPR65 retains its native structure and function for downstream applications.

How should researchers interpret differences in signaling profiles between protons, psychosine, and synthetic agonists when activating GPR65?

The interpretation of differential signaling profiles requires careful consideration of biased agonism concepts:

• Signaling Fingerprint Comparison:
  Analyze the maximum effect (Emax) and potency (EC50) across multiple pathways to create a comprehensive signaling profile for each agonist. Based on published data:

  Signaling Pathway	Protons	BTB09089	Psychosine
  cAMP Accumulation	+++	+++	++
  Ca2+ Mobilization	+++	+++	+
  ERK1/2 Phosphorylation	+++	+++	++
  β-arrestin 1 Recruitment	+++	+++	-
  β-arrestin 2 Recruitment	+++	+++	-
  Receptor Internalization	+++	++	+

  This pattern indicates that BTB09089 most closely mimics proton-induced signaling, while psychosine shows a distinct bias away from β-arrestin recruitment pathways .

• Receptor Conformational States:
  Different ligands likely stabilize distinct receptor conformational states, resulting in preferential coupling to specific downstream effectors. The absence of psychosine-induced β-arrestin recruitment suggests it induces a conformation that doesn't expose the intracellular domains recognized by arrestins.

• Physiological Relevance:
  Consider the biological context - psychosine accumulates pathologically in Krabbe disease , while protons increase in inflammatory environments. These different contexts may require distinct signaling outcomes, explaining the evolved ligand bias.

• Experimental Considerations:

  • Ensure all measurements are made under comparable conditions

  • Control for potential off-target effects, particularly with higher concentrations of synthetic compounds

  • Validate key findings using multiple methodological approaches

These distinctions in signaling profiles have important implications for drug development targeting GPR65, as they suggest opportunities for biased ligands that selectively modulate beneficial pathways while avoiding detrimental ones.

What are the common technical challenges in working with recombinant GPR65 and how can they be addressed?

Working with recombinant GPR65 presents several technical challenges inherent to membrane protein research:

• Low Expression Yields:

  • Challenge: GPCRs often express poorly in heterologous systems

  • Solution: Optimize codon usage for the expression system; use specialized expression vectors containing chaperon-binding domains; test multiple cell lines; implement temperature shifts during expression; consider fusion partners (T4 lysozyme, BRIL) to enhance stability

• Protein Aggregation:

  • Challenge: Transmembrane proteins tend to aggregate during purification

  • Solution: Screen multiple detergents and lipid combinations; use GFP-fusion screening to monitor monodispersity; implement size-exclusion chromatography as a final purification step; consider nanodiscs or styrene maleic acid lipid particles (SMALPs) for stabilization

• Loss of Functional Activity:

  • Challenge: Recombinant GPR65 may lose activity during purification

  • Solution: Validate function at each purification stage; preserve native lipid environment when possible; include stabilizing ligands during purification; consider thermostability assays to identify optimal buffer conditions

• Inconsistent Signaling Responses:

  • Challenge: Variable results in signaling assays

  • Solution: Carefully control cell density and passage number; ensure consistent receptor expression levels through flow cytometry or western blotting; include internal standards; normalize responses to total protein or cell number

• Non-specific Binding in Immunoassays:

  • Challenge: High background in detection assays

  • Solution: Implement rigorous blocking protocols; use monoclonal antibodies when available; validate antibody specificity with knockout controls; consider epitope tags for consistent detection

By anticipating and addressing these challenges, researchers can significantly improve the reliability and reproducibility of experiments involving recombinant GPR65.

How can researchers effectively analyze and quantify GPR65-mediated effects in complex cellular systems or animal models?

Analyzing GPR65-mediated effects in complex systems requires integrative approaches that combine molecular, cellular, and behavioral readouts:

• Cell-Type Specific Isolation and Analysis:

  • Implement FACS-based isolation of specific cell populations from tissues

  • Use single-cell RNA sequencing to identify GPR65-expressing cells and their transcriptional responses

  • Apply laser capture microdissection for spatial resolution of responses

• Multiplexed Molecular Profiling:

  • Employ RNA-seq or proteomics to characterize global response patterns

  • Use phosphoproteomics to map GPR65-triggered signaling networks

  • Implement cytokine/chemokine arrays to quantify secreted factors

• Genetic Approaches for Causality Testing:

  • Generate conditional knockout models using Cre-LoxP systems

  • Apply GPR65 overexpression in specific cell types

  • Use CRISPR/Cas9 for precise genetic manipulation

• Quantitative Assessment in Animal Models:

  • For pain studies: Use objective measures such as von Frey filaments, rotarod testing, and wire-hang tests, as demonstrated in Krabbe disease models (wire-hang maximum tested time: 60s)

  • For inflammatory markers: Quantify tissue immunohistochemistry using standardized scoring systems

  • For behavioral changes: Implement automated systems for unbiased assessment

• Pharmacological Validation:

  • Use selective agonists (BTB09089) at 1-10 μM concentration

  • Apply emerging GPR65 antagonists as controls

  • Consider dose-response relationships to establish causality

• Translational Validation:

  • Test findings in human samples (e.g., synovial fluid from osteoarthritis patients)

  • Correlate animal findings with human disease manifestations

  • Consider species differences in GPR65 expression and function

This multilevel approach provides robust evidence for GPR65-specific effects while accounting for the inherent complexity of physiological systems.

What is known about the structural basis of ligand selectivity and biased signaling at GPR65?

Current understanding of GPR65 structure-function relationships remains limited, but emerging data provides insights into ligand selectivity and biased signaling:

• Ligand Binding Pocket Characteristics:

  • The proton-sensing capability likely involves histidine residues in the extracellular domains that act as pH sensors

  • Psychosine, being a glycosphingolipid, likely interacts with both polar and hydrophobic regions within the binding pocket

  • BTB09089's selective activity suggests a unique binding mode that distinguishes GPR65 from other proton-sensing GPCRs

• Structural Determinants of Biased Signaling:

  • The differential β-arrestin recruitment observed between ligands (present for protons/BTB, absent for psychosine) indicates distinct conformational states

  • Specific intracellular loop regions likely adopt different orientations depending on the bound ligand

  • These conformational differences presumably affect coupling to G-proteins versus arrestins

• Molecular Dynamics Insights:

  • While no crystal structure exists for GPR65, homology modeling based on related GPCRs suggests:

    • A typical 7-transmembrane domain structure

    • Extracellular loops forming the entrance to the binding pocket

    • Intracellular regions coupling to signaling partners

• Future Structural Approaches:

  • Cryo-EM represents a promising approach for determining GPR65 structure

  • Hydrogen-deuterium exchange mass spectrometry could map conformational changes

  • Cross-linking studies may identify key interaction sites for different ligands

Advancing structural knowledge will be crucial for developing selective modulators of GPR65 function and understanding the molecular basis of biased signaling.

How does GPR65 signaling interact with other inflammatory pathways in chronic disease models?

GPR65 signaling does not operate in isolation but rather integrates with multiple inflammatory pathways:

• Cytokine Network Interactions:

  • GPR65 activation on fibroblast-like synoviocytes (FLS) triggers secretion of proinflammatory mediators

  • These cytokines form feedback loops that can amplify inflammatory responses

  • GPR65-mediated responses may synergize with TNF-α, IL-1β, and IL-6 pathways

• Neuronal Sensitization Mechanisms:

  • GPR65 activation contributes to neuronal sensitization through direct and indirect mechanisms

  • Direct effects may occur through GPR65 expressed on sensory neurons

  • Indirect effects involve GPR65-activated cells releasing factors that sensitize neurons

• Acid-Sensing Ion Channel (ASIC) Crosstalk:

  • Protons activate both GPR65 and ASICs in inflammatory environments

  • These pathways may converge on common downstream targets

  • Combined inhibition may provide enhanced anti-inflammatory effects

• Immune Cell Recruitment and Activation:

  • GPR65 signaling affects immune cell function in acidic microenvironments

  • This may modulate the composition and activity of tissue-infiltrating leukocytes

  • T-cell responses may be particularly affected given GPR65's alternative name (TDAG8)

• Relevance to Specific Disease Models:

  • Inflammatory arthritis: GPR65 mediates joint pain and inflammation

  • Krabbe disease: Psychosine (which accumulates due to GALC deficiency) activates GPR65, potentially contributing to pathology

  • Other acidosis-associated conditions: GPR65 may play roles in ischemia, cancer, and autoimmune diseases

Understanding these pathway interactions will be essential for developing targeted therapies that modulate GPR65 signaling in specific disease contexts.

What are the emerging therapeutic opportunities targeting GPR65 in inflammatory and neurological disorders?

Emerging research suggests several promising therapeutic approaches targeting GPR65:

• Selective Antagonism:

  • Development of small molecule GPR65 antagonists could block inflammatory signaling

  • Potential applications in inflammatory joint diseases, where GPR65 mediates pain through cell-cell interactions

  • Challenges include achieving selectivity against other proton-sensing receptors

• Biased Ligand Development:

  • Given the distinct signaling profiles of different ligands, developing compounds that selectively activate beneficial pathways while avoiding detrimental ones

  • Potential to separate anti-inflammatory effects from pro-nociceptive effects

• Cell-Type Specific Targeting:

  • Delivery systems that preferentially target GPR65 modulators to specific cell types (e.g., fibroblast-like synoviocytes)

  • This approach could reduce off-target effects while enhancing therapeutic efficacy

• Combination Therapies:

  • In Krabbe disease, combining GPR65 antagonism with other approaches like substrate reduction therapy (targeting acid ceramidase)

  • For inflammatory diseases, pairing GPR65 modulation with established anti-inflammatory agents

• Diagnostic Applications:

  • Developing imaging agents that bind GPR65 to visualize inflammatory sites

  • Creating biomarker assays based on GPR65 activation or downstream effects

• Translational Considerations:

  • Species differences in GPR65 pharmacology must be addressed in preclinical studies

  • Patient stratification based on GPR65 expression or activity could identify responsive subgroups

  • Safety considerations include potential impacts on immune surveillance and acid-base homeostasis

These therapeutic opportunities highlight the potential of GPR65 as a novel target for treating inflammatory and neurological conditions with significant unmet medical needs.

What are the optimal protocols for measuring psychosine levels in biological samples from GPR65 experimental models?

Accurate quantification of psychosine requires specialized analytical methods:

• Sample Preparation:

  • Homogenize tissue samples in 0.9% sodium chloride solution

  • Add internal standard (1 nM d5-psychosine) and incubate for 2 hours

  • Centrifuge at 13,000 rcf for 5 minutes

  • Process supernatant through solid-phase extraction (SPE) cleanup

  • Dry samples using speedvac

• UPLC-MS/MS Analysis:

  • Reconstitute dried samples in mobile phase B solution

  • Separate compounds using ultra-performance liquid chromatography

  • Detect and quantify using tandem mass spectrometry (MS/MS)

  • Use multiple reaction monitoring (MRM) for high sensitivity and specificity

• Validation Parameters:

  • Establish standard curves using purified psychosine

  • Determine limits of detection and quantification

  • Assess intra- and inter-assay variability

  • Confirm absence of matrix effects

• Data Analysis and Interpretation:

  • Normalize results to protein concentration or tissue weight

  • Compare to appropriate controls (wild-type, disease models)

  • Consider age-dependent changes in psychosine levels

This methodology allows for accurate quantification of psychosine in various tissues, including brain, sciatic nerve, liver, and spleen, enabling correlation of psychosine levels with GPR65 activation status in experimental models .

How can researchers effectively design and interpret GPR65 knockout or knockdown experiments?

Designing rigorous genetic manipulation studies for GPR65 requires careful consideration of multiple factors:

• Model Selection:

  • Global knockout: Useful for understanding systemic roles but may have compensatory mechanisms

  • Conditional knockout: Allows tissue- or time-specific deletion to avoid developmental effects

  • Knockdown: Provides intermediate reduction in expression, potentially avoiding complete loss-of-function consequences

• Validation Strategy:

  • Genomic verification: PCR-based genotyping with specific primers

  • RNA expression: RT-qPCR to confirm transcript reduction

  • Protein expression: Western blotting or immunohistochemistry

  • Functional validation: Measure responses to selective agonists (BTB09089)

• Control Selection:

  • Wild-type littermates as primary controls

  • Heterozygous animals to assess gene dosage effects

  • Rescue experiments through re-expression to confirm phenotype specificity

• Phenotypic Analysis:

  • Comprehensive assessment across multiple systems

  • Baseline versus challenged conditions (e.g., inflammatory stimuli)

  • Age-dependent phenotypes

  • Sex-specific differences

• Interpretation Considerations:

  • Distinguish direct versus indirect effects

  • Consider compensatory mechanisms (e.g., upregulation of other proton sensors)

  • Assess cell-autonomous versus non-cell-autonomous effects

  • Interpret behavioral changes in the context of molecular and cellular alterations

The Twi/FD mouse model (GALC-/-, Asah1-/-) provides an excellent example of genetic manipulation to study related pathways, demonstrating how double-knockout approaches can reveal functional relationships between interconnected systems .

What advanced imaging techniques can be applied to study GPR65 localization and trafficking in live cells?

Advanced imaging approaches provide powerful tools for investigating GPR65 dynamics:

• Super-Resolution Microscopy:

  • Stimulated Emission Depletion (STED) microscopy: Achieves resolution down to ~50 nm

  • Photoactivated Localization Microscopy (PALM): Uses photoactivatable fluorophores for single-molecule localization

  • Stochastic Optical Reconstruction Microscopy (STORM): Provides nanoscale resolution for tracking receptor clusters

• Live-Cell Fluorescence Techniques:

  • Total Internal Reflection Fluorescence (TIRF): Visualizes membrane-proximal events with high signal-to-noise ratio

  • Fluorescence Recovery After Photobleaching (FRAP): Measures lateral mobility of GPR65 in the membrane

  • Fluorescence Correlation Spectroscopy (FCS): Analyzes diffusion characteristics and molecular interactions

• Resonance Energy Transfer Approaches:

  • Förster Resonance Energy Transfer (FRET): Detects molecular proximity between GPR65 and interaction partners

  • Bioluminescence Resonance Energy Transfer (BRET): Monitors interactions without external illumination, reducing phototoxicity

  • BRET assays with GPR65-RLuc8 and β-arrestin-YFP or RIT-Venus constructs have been successfully implemented

• Spatiotemporal Analysis Tools:

  • Fluorescence Lifetime Imaging Microscopy (FLIM): Measures the excited-state lifetime of fluorophores, providing information independent of concentration

  • Single-Particle Tracking (SPT): Follows individual receptor molecules to analyze movement patterns

  • Optogenetic approaches: Allows precise temporal control of GPR65 activation

• Multi-Modal Imaging:

  • Correlative Light and Electron Microscopy (CLEM): Combines fluorescence localization with ultrastructural context

  • Expansion Microscopy: Physically enlarges specimens to improve resolution with standard equipment

These advanced imaging approaches enable researchers to visualize GPR65 trafficking from the cell surface to endosomal compartments, determine its interactions with signaling partners, and assess how these dynamics change in response to different ligands or cellular conditions.

Frequently Asked Questions (FAQs) for Researchers: Recombinant Mouse Psychosine Receptor (GPR65)

This comprehensive FAQ collection addresses common research questions about the recombinant mouse psychosine receptor (GPR65), ranging from basic characterization to advanced experimental approaches. These questions reflect actual research scenarios encountered in laboratory settings and provide methodologically oriented answers based on recent scientific literature.

What is GPR65 and what are its primary functions in physiological systems?

GPR65 (also known as T-cell death-associated gene 8 or TDAG8) is a proton-sensing G-protein-coupled receptor (PS-GPCR) that plays significant roles in inflammatory and immune processes. It functions as a pH sensor, becoming activated in acidic environments typical of inflammatory sites. When activated, GPR65 triggers multiple downstream signaling cascades that mediate inflammatory responses, including cytokine production and cellular activation .

In physiological systems, GPR65 has been implicated in:

• Mediating inflammatory joint pain through cell-cell interactions

• Coordinating immune cell function in acidic microenvironments

• Sensitizing sensory neurons in inflammatory conditions

• Possibly regulating T-cell apoptosis (hence its alternative name TDAG8)

Recent research has demonstrated that GPR65 on fibroblast-like synoviocytes (FLS) contributes to inflammatory joint pain by secreting proinflammatory mediators that sensitize sensory neurons and recruit additional immune cells .

How does psychosine interact with GPR65, and what are the alternative ligands for this receptor?

Known activators of GPR65 include:

• Protons (H+) - The primary physiological activator, functioning optimally at pH 6.0-6.5

• Psychosine - A glycosphingolipid that accumulates in Krabbe disease

• BTB09089 (BTB) - A synthetic agonist with high selectivity for GPR65

Notably, while protons and BTB both induce robust cAMP accumulation, calcium mobilization, ERK1/2 phosphorylation, and β-arrestin recruitment, psychosine shows a different signaling profile. For instance, psychosine fails to coordinate β-arrestin recruitment to GPR65 while still triggering receptor internalization, suggesting ligand-specific activation mechanisms .

What experimental methods are used to express and purify recombinant mouse GPR65?

Expression and purification of recombinant mouse GPR65 typically employs mammalian expression systems due to the complex post-translational modifications required for proper GPCR folding and function. The methodology involves:

• Vector Construction:

  • Cloning full-length mouse GPR65 cDNA into a mammalian expression vector

  • Including appropriate tags (such as V5 or polyhistidine) for detection and purification

• Cell Line Selection and Transfection:

  • Chinese Hamster Ovary (CHO) cells are commonly used for GPCR expression

  • Stable transfection followed by selection of high-expressing clones

• Expression Optimization:

  • Culturing in chemically defined medium in suspension

  • Fed-batch production with additional feeds and glucose over 10-14 days

• Purification Strategy:

  • Harvesting and filtering cell culture fluid

  • Two-step chromatographic purification using ion exchange (e.g., Capto Q) followed by hydrophobic interaction chromatography (e.g., Butyl Sepharose)

  • pH adjustment and sterile filtration

  • Concentration using centrifugal spin concentrators

This approach mirrors successful strategies used for other membrane proteins, including recombinant acid ceramidase production in CHO cells as described in the literature .

How can researchers effectively distinguish between GPR65-specific signaling and responses mediated by other proton-sensing receptors?

Differentiating GPR65-specific signaling from other proton-sensing receptors requires a multi-faceted approach that leverages selective tools and genetic models:

• Use of Selective Agonists:

  • BTB09089 (BTB) has been validated as a selective GPR65 agonist that recapitulates many proton-induced signaling events without activating other proton-sensing receptors

  • BTB shows activation only in cells expressing mGPR65 and not in control cells (mGPR65-CHO vs. CHO: P-adj < 0.0001)

• CRISPR/Cas9 Knockout Validation:

  • Generate GPR65 knockout cell lines to confirm specificity

  • Compare responses between wild-type, knockout, and rescued (re-expressing GPR65) cell lines

• Signaling Fingerprint Analysis:

  • Monitor multiple downstream pathways simultaneously (cAMP, Ca2+, ERK1/2, β-arrestin recruitment)

  • The specific pattern of activation across pathways can distinguish GPR65 from other proton sensors

  • For example, assess ERK1/2 phosphorylation in both parental and GPR65-expressing cells (pH 6: Flp-IN, 1.11 ± 0.15%, mGPR65-CHO, 39.51 ± 2.16%, t = −17.756, df = 2.018, P = 0.003)

• BRET-Based Interaction Assays:

  • Implement Bioluminescence Resonance Energy Transfer (BRET) assays to directly measure:

    • β-arrestin recruitment (using GPR65-RLuc8 and β-arrestin-YFP constructs)

    • Receptor internalization (using GPR65-RLuc8 and membrane-targeted RIT-Venus)

This comprehensive approach allows researchers to confidently attribute observed responses to GPR65 rather than other proton-sensing mechanisms.

What are the optimal experimental conditions for analyzing GPR65-mediated signaling in primary cell cultures?

Establishing optimal conditions for GPR65 signaling analysis in primary cells requires careful consideration of multiple parameters:

• pH Control and Buffering Systems:

  • Maintain precise pH control (typically pH 6.0-6.5 for proton activation)

  • Use Good's buffers (MES, PIPES) for stable pH maintenance

  • Include proper controls at physiological pH (7.2-7.4)

• Primary Cell Isolation and Culture:

  • For fibroblast-like synoviocytes (FLS): enzymatic digestion of synovial tissue with collagenase, followed by adherence selection

  • For sensory neurons: dissociation of dorsal root ganglia with specific growth factor supplementation

  • Maintain cells in serum-free conditions during experiments to avoid confounding factors

• Signaling Readout Selection:

  • cAMP accumulation: use ELISA or HTRF-based detection after phosphodiesterase inhibition

  • Ca2+ mobilization: employ ratiometric imaging with Fura-2 or fluorescent plate readers with Fluo-4

  • ERK1/2 phosphorylation: western blotting or in-cell western techniques

  • Cytokine secretion: multiplex assays to capture the full profile of released mediators

• Temporal Considerations:

  • Perform time-course experiments (5-60 minutes) to capture both early and late signaling events

  • For long-term outcomes, monitor cells for 24-72 hours under controlled conditions

• Pharmacological Tools:

  • Use BTB09089 at 1-10 μM as a selective GPR65 agonist

  • Include appropriate vehicle controls

  • Consider antagonist studies with emerging GPR65 inhibitors to confirm receptor specificity

These conditions allow for robust and reproducible analysis of GPR65 signaling in physiologically relevant primary cell systems.

How can recombinant GPR65 be functionally validated to ensure proper folding and signaling capacity?

Functional validation of recombinant GPR65 requires a systematic approach to confirm proper protein folding, membrane localization, and signaling competence:

• Conformational Analysis:

  • Circular dichroism spectroscopy to assess secondary structure

  • Limited proteolysis to evaluate the accessibility of protease sites

  • Thermal stability assays to determine protein stability

• Membrane Localization Assessment:

  • Confocal microscopy with fluorescently tagged GPR65

  • Surface biotinylation followed by western blotting

  • BRET assays using RIT-Venus as a plasma membrane marker

• Ligand Binding Assays:

  • Radioligand binding assays (if available)

  • Fluorescent ligand binding with FRET-based detection

  • Surface plasmon resonance for direct binding kinetics

• Signaling Competence Validation:

  • cAMP accumulation assays in response to protons, BTB09089, and psychosine

  • Dose-response curves across multiple signaling pathways

• Functional Reconstitution:

  • Expression in GPR65-null cells to rescue phenotypes

  • Comparison with native receptor responses in appropriate cell types

Through this comprehensive validation approach, researchers can ensure that recombinant GPR65 retains its native structure and function for downstream applications.

How should researchers interpret differences in signaling profiles between protons, psychosine, and synthetic agonists when activating GPR65?

The interpretation of differential signaling profiles requires careful consideration of biased agonism concepts:

• Signaling Fingerprint Comparison:
  Analyze the maximum effect (Emax) and potency (EC50) across multiple pathways to create a comprehensive signaling profile for each agonist. Based on published data:

  Signaling Pathway	Protons	BTB09089	Psychosine
  cAMP Accumulation	+++	+++	++
  Ca2+ Mobilization	+++	+++	+
  ERK1/2 Phosphorylation	+++	+++	++
  β-arrestin 1 Recruitment	+++	+++	-
  β-arrestin 2 Recruitment	+++	+++	-
  Receptor Internalization	+++	++	+

  This pattern indicates that BTB09089 most closely mimics proton-induced signaling, while psychosine shows a distinct bias away from β-arrestin recruitment pathways .

• Receptor Conformational States:
  Different ligands likely stabilize distinct receptor conformational states, resulting in preferential coupling to specific downstream effectors. The absence of psychosine-induced β-arrestin recruitment suggests it induces a conformation that doesn't expose the intracellular domains recognized by arrestins.

• Physiological Relevance:
  Consider the biological context - psychosine accumulates pathologically in Krabbe disease , while protons increase in inflammatory environments. These different contexts may require distinct signaling outcomes, explaining the evolved ligand bias.

• Experimental Considerations:

  • Ensure all measurements are made under comparable conditions

  • Control for potential off-target effects, particularly with higher concentrations of synthetic compounds

  • Validate key findings using multiple methodological approaches

These distinctions in signaling profiles have important implications for drug development targeting GPR65, as they suggest opportunities for biased ligands that selectively modulate beneficial pathways while avoiding detrimental ones.

What are the common technical challenges in working with recombinant GPR65 and how can they be addressed?

Working with recombinant GPR65 presents several technical challenges inherent to membrane protein research:

• Low Expression Yields:

  • Challenge: GPCRs often express poorly in heterologous systems

  • Solution: Optimize codon usage for the expression system; use specialized expression vectors containing chaperon-binding domains; test multiple cell lines; implement temperature shifts during expression; consider fusion partners (T4 lysozyme, BRIL) to enhance stability

• Protein Aggregation:

  • Challenge: Transmembrane proteins tend to aggregate during purification

  • Solution: Screen multiple detergents and lipid combinations; use GFP-fusion screening to monitor monodispersity; implement size-exclusion chromatography as a final purification step; consider nanodiscs or styrene maleic acid lipid particles (SMALPs) for stabilization

• Loss of Functional Activity:

  • Challenge: Recombinant GPR65 may lose activity during purification

  • Solution: Validate function at each purification stage; preserve native lipid environment when possible; include stabilizing ligands during purification; consider thermostability assays to identify optimal buffer conditions

• Inconsistent Signaling Responses:

  • Challenge: Variable results in signaling assays

  • Solution: Carefully control cell density and passage number; ensure consistent receptor expression levels through flow cytometry or western blotting; include internal standards; normalize responses to total protein or cell number

• Non-specific Binding in Immunoassays:

  • Challenge: High background in detection assays

  • Solution: Implement rigorous blocking protocols; use monoclonal antibodies when available; validate antibody specificity with knockout controls; consider epitope tags for consistent detection

By anticipating and addressing these challenges, researchers can significantly improve the reliability and reproducibility of experiments involving recombinant GPR65.

How can researchers effectively analyze and quantify GPR65-mediated effects in complex cellular systems or animal models?

Analyzing GPR65-mediated effects in complex systems requires integrative approaches that combine molecular, cellular, and behavioral readouts:

• Cell-Type Specific Isolation and Analysis:

  • Implement FACS-based isolation of specific cell populations from tissues

  • Use single-cell RNA sequencing to identify GPR65-expressing cells and their transcriptional responses

  • Apply laser capture microdissection for spatial resolution of responses

• Multiplexed Molecular Profiling:

  • Employ RNA-seq or proteomics to characterize global response patterns

  • Use phosphoproteomics to map GPR65-triggered signaling networks

  • Implement cytokine/chemokine arrays to quantify secreted factors

• Genetic Approaches for Causality Testing:

  • Generate conditional knockout models using Cre-LoxP systems

  • Apply GPR65 overexpression in specific cell types

  • Use CRISPR/Cas9 for precise genetic manipulation

• Quantitative Assessment in Animal Models:

  • For pain studies: Use objective measures such as von Frey filaments, rotarod testing, and wire-hang tests, as demonstrated in Krabbe disease models (wire-hang maximum tested time: 60s)

  • For inflammatory markers: Quantify tissue immunohistochemistry using standardized scoring systems

  • For behavioral changes: Implement automated systems for unbiased assessment

• Pharmacological Validation:

  • Use selective agonists (BTB09089) at 1-10 μM concentration

  • Apply emerging GPR65 antagonists as controls

  • Consider dose-response relationships to establish causality

• Translational Validation:

  • Test findings in human samples (e.g., synovial fluid from osteoarthritis patients)

  • Correlate animal findings with human disease manifestations

  • Consider species differences in GPR65 expression and function

This multilevel approach provides robust evidence for GPR65-specific effects while accounting for the inherent complexity of physiological systems.

What is known about the structural basis of ligand selectivity and biased signaling at GPR65?

Current understanding of GPR65 structure-function relationships remains limited, but emerging data provides insights into ligand selectivity and biased signaling:

• Ligand Binding Pocket Characteristics:

  • The proton-sensing capability likely involves histidine residues in the extracellular domains that act as pH sensors

  • Psychosine, being a glycosphingolipid, likely interacts with both polar and hydrophobic regions within the binding pocket

  • BTB09089's selective activity suggests a unique binding mode that distinguishes GPR65 from other proton-sensing GPCRs

• Structural Determinants of Biased Signaling:

  • The differential β-arrestin recruitment observed between ligands (present for protons/BTB, absent for psychosine) indicates distinct conformational states

  • Specific intracellular loop regions likely adopt different orientations depending on the bound ligand

  • These conformational differences presumably affect coupling to G-proteins versus arrestins

• Molecular Dynamics Insights:

  • While no crystal structure exists for GPR65, homology modeling based on related GPCRs suggests:

    • A typical 7-transmembrane domain structure

    • Extracellular loops forming the entrance to the binding pocket

    • Intracellular regions coupling to signaling partners

• Future Structural Approaches:

  • Cryo-EM represents a promising approach for determining GPR65 structure

  • Hydrogen-deuterium exchange mass spectrometry could map conformational changes

  • Cross-linking studies may identify key interaction sites for different ligands

Advancing structural knowledge will be crucial for developing selective modulators of GPR65 function and understanding the molecular basis of biased signaling.

How does GPR65 signaling interact with other inflammatory pathways in chronic disease models?

GPR65 signaling does not operate in isolation but rather integrates with multiple inflammatory pathways:

• Cytokine Network Interactions:

  • GPR65 activation on fibroblast-like synoviocytes (FLS) triggers secretion of proinflammatory mediators

  • These cytokines form feedback loops that can amplify inflammatory responses

  • GPR65-mediated responses may synergize with TNF-α, IL-1β, and IL-6 pathways

• Neuronal Sensitization Mechanisms:

  • GPR65 activation contributes to neuronal sensitization through direct and indirect mechanisms

  • Direct effects may occur through GPR65 expressed on sensory neurons

  • Indirect effects involve GPR65-activated cells releasing factors that sensitize neurons

• Acid-Sensing Ion Channel (ASIC) Crosstalk:

  • Protons activate both GPR65 and ASICs in inflammatory environments

  • These pathways may converge on common downstream targets

  • Combined inhibition may provide enhanced anti-inflammatory effects

• Immune Cell Recruitment and Activation:

  • GPR65 signaling affects immune cell function in acidic microenvironments

  • This may modulate the composition and activity of tissue-infiltrating leukocytes

  • T-cell responses may be particularly affected given GPR65's alternative name (TDAG8)

• Relevance to Specific Disease Models:

  • Inflammatory arthritis: GPR65 mediates joint pain and inflammation

  • Krabbe disease: Psychosine (which accumulates due to GALC deficiency) activates GPR65, potentially contributing to pathology

  • Other acidosis-associated conditions: GPR65 may play roles in ischemia, cancer, and autoimmune diseases

Understanding these pathway interactions will be essential for developing targeted therapies that modulate GPR65 signaling in specific disease contexts.

What are the emerging therapeutic opportunities targeting GPR65 in inflammatory and neurological disorders?

Emerging research suggests several promising therapeutic approaches targeting GPR65:

• Selective Antagonism:

  • Development of small molecule GPR65 antagonists could block inflammatory signaling

  • Potential applications in inflammatory joint diseases, where GPR65 mediates pain through cell-cell interactions

  • Challenges include achieving selectivity against other proton-sensing receptors

• Biased Ligand Development:

  • Given the distinct signaling profiles of different ligands, developing compounds that selectively activate beneficial pathways while avoiding detrimental ones

  • Potential to separate anti-inflammatory effects from pro-nociceptive effects

• Cell-Type Specific Targeting:

  • Delivery systems that preferentially target GPR65 modulators to specific cell types (e.g., fibroblast-like synoviocytes)

  • This approach could reduce off-target effects while enhancing therapeutic efficacy

• Combination Therapies:

  • In Krabbe disease, combining GPR65 antagonism with other approaches like substrate reduction therapy (targeting acid ceramidase)

  • For inflammatory diseases, pairing GPR65 modulation with established anti-inflammatory agents

• Diagnostic Applications:

  • Developing imaging agents that bind GPR65 to visualize inflammatory sites

  • Creating biomarker assays based on GPR65 activation or downstream effects

• Translational Considerations:

  • Species differences in GPR65 pharmacology must be addressed in preclinical studies

  • Patient stratification based on GPR65 expression or activity could identify responsive subgroups

  • Safety considerations include potential impacts on immune surveillance and acid-base homeostasis

These therapeutic opportunities highlight the potential of GPR65 as a novel target for treating inflammatory and neurological conditions with significant unmet medical needs.

What are the optimal protocols for measuring psychosine levels in biological samples from GPR65 experimental models?

Accurate quantification of psychosine requires specialized analytical methods:

• Sample Preparation:

  • Homogenize tissue samples in 0.9% sodium chloride solution

  • Add internal standard (1 nM d5-psychosine) and incubate for 2 hours

  • Centrifuge at 13,000 rcf for 5 minutes

  • Process supernatant through solid-phase extraction (SPE) cleanup

  • Dry samples using speedvac

• UPLC-MS/MS Analysis:

  • Reconstitute dried samples in mobile phase B solution

  • Separate compounds using ultra-performance liquid chromatography

  • Detect and quantify using tandem mass spectrometry (MS/MS)

  • Use multiple reaction monitoring (MRM) for high sensitivity and specificity

• Validation Parameters:

  • Establish standard curves using purified psychosine

  • Determine limits of detection and quantification

  • Assess intra- and inter-assay variability

  • Confirm absence of matrix effects

• Data Analysis and Interpretation:

  • Normalize results to protein concentration or tissue weight

  • Compare to appropriate controls (wild-type, disease models)

  • Consider age-dependent changes in psychosine levels

This methodology allows for accurate quantification of psychosine in various tissues, including brain, sciatic nerve, liver, and spleen, enabling correlation of psychosine levels with GPR65 activation status in experimental models .

How can researchers effectively design and interpret GPR65 knockout or knockdown experiments?

Designing rigorous genetic manipulation studies for GPR65 requires careful consideration of multiple factors:

• Model Selection:

  • Global knockout: Useful for understanding systemic roles but may have compensatory mechanisms

  • Conditional knockout: Allows tissue- or time-specific deletion to avoid developmental effects

  • Knockdown: Provides intermediate reduction in expression, potentially avoiding complete loss-of-function consequences

• Validation Strategy:

  • Genomic verification: PCR-based genotyping with specific primers

  • RNA expression: RT-qPCR to confirm transcript reduction

  • Protein expression: Western blotting or immunohistochemistry

  • Functional validation: Measure responses to selective agonists (BTB09089)

• Control Selection:

  • Wild-type littermates as primary controls

  • Heterozygous animals to assess gene dosage effects

  • Rescue experiments through re-expression to confirm phenotype specificity

• Phenotypic Analysis:

  • Comprehensive assessment across multiple systems

  • Baseline versus challenged conditions (e.g., inflammatory stimuli)

  • Age-dependent phenotypes

  • Sex-specific differences

• Interpretation Considerations:

  • Distinguish direct versus indirect effects

  • Consider compensatory mechanisms (e.g., upregulation of other proton sensors)

  • Assess cell-autonomous versus non-cell-autonomous effects

  • Interpret behavioral changes in the context of molecular and cellular alterations

The Twi/FD mouse model (GALC-/-, Asah1-/-) provides an excellent example of genetic manipulation to study related pathways, demonstrating how double-knockout approaches can reveal functional relationships between interconnected systems .

What advanced imaging techniques can be applied to study GPR65 localization and trafficking in live cells?

Advanced imaging approaches provide powerful tools for investigating GPR65 dynamics:

• Super-Resolution Microscopy:

  • Stimulated Emission Depletion (STED) microscopy: Achieves resolution down to ~50 nm

  • Photoactivated Localization Microscopy (PALM): Uses photoactivatable fluorophores for single-molecule localization

  • Stochastic Optical Reconstruction Microscopy (STORM): Provides nanoscale resolution for tracking receptor clusters

• Live-Cell Fluorescence Techniques:

  • Total Internal Reflection Fluorescence (TIRF): Visualizes membrane-proximal events with high signal-to-noise ratio

  • Fluorescence Recovery After Photobleaching (FRAP): Measures lateral mobility of GPR65 in the membrane

  • Fluorescence Correlation Spectroscopy (FCS): Analyzes diffusion characteristics and molecular interactions

• Resonance Energy Transfer Approaches:

  • Förster Resonance Energy Transfer (FRET): Detects molecular proximity between GPR65 and interaction partners

  • Bioluminescence Resonance Energy Transfer (BRET): Monitors interactions without external illumination, reducing phototoxicity

  • BRET assays with GPR65-RLuc8 and β-arrestin-YFP or RIT-Venus constructs have been successfully implemented

• Spatiotemporal Analysis Tools:

  • Fluorescence Lifetime Imaging Microscopy (FLIM): Measures the excited-state lifetime of fluorophores, providing information independent of concentration

  • Single-Particle Tracking (SPT): Follows individual receptor molecules to analyze movement patterns

  • Optogenetic approaches: Allows precise temporal control of GPR65 activation

• Multi-Modal Imaging:

  • Correlative Light and Electron Microscopy (CLEM): Combines fluorescence localization with ultrastructural context

  • Expansion Microscopy: Physically enlarges specimens to improve resolution with standard equipment

These advanced imaging approaches enable researchers to visualize GPR65 trafficking from the cell surface to endosomal compartments, determine its interactions with signaling partners, and assess how these dynamics change in response to different ligands or cellular conditions.